![Tusch [Fanfare]](https://conscienhealth.org/wp-content/uploads/2024/08/Tusch-Fanfare-501x334.jpg)
August 17, 2024 — Never is a long time and repeatedly telling people NO can be a futile exercise. Thus, doctors are landing somewhere between no and maybe on the use of compounded obesity medicines. Some are seeing a rationale for for using them while others remain resolute in opposition to them. Shauna Levy is an obesity medicine physician […]
December 30, 2023 — FDA tells us we have a problem – actually two of them, and they’re connected to a third. First, counterfeit versions of the Ozempic brand of semaglutide injections are finding their way into pharmacies. These fakes present an inherent risk of problems with safety and effectiveness. Second, compounded versions of semaglutide are selling in some […]
December 26, 2023 — In the New Yorker, Dhruv Khullar calls 2023 “the year of Ozempic.” Then in Vox, Constance Grady puts it right up there with Barbie, calling this “the year of Ozempic bodies and Barbie Botox.” The New York Times puts it at the very top of five health lessons we learned in 2023. Most notably, Science […]
December 21, 2023 — No two ways about it. This has been a big year of milestones in obesity and health. We and many others are still processing what we have witnessed in these past 12 months. But one way to gain perspective is to look at 2023 stats for the posts on ConscienHealth that you, a wise group […]
November 25, 2023 — Two weeks ago, a shift started in the public messaging about semaglutide supply issues that have dogged Novo Nordisk from the very beginning of launching a version of this drug (Wegovy) for obesity. Has the catch-up game in production capacity for obesity and diabetes medicines begun at last in earnest? At the beginning of November, […]
November 3, 2023 — Novo Nordisk and Eli Lilly updated their investors yesterday on their performance through the third quarter of 2023 and the word is that they are “raking in cash” from their new medicines that work so well in obesity. Gobs of money seem to be flowing to both companies, but the stories they were telling about […]
October 30, 2023 — It leaves our heads spinning. Normal healthcare systems cannot keep up with the demand for a breakthrough in obesity treatment. The company, Novo Nordisk, which developed semaglutide for obesity treatment, has invested billions and now is reaping many billions of dollars in sales. But despite more than a decade of preparation, they can’t keep up. […]
October 16, 2023 — Forgive us a bit of skepticism please. We are facing a jarring disconnect at ObesityWeek from the reality of medical care that simply can’t keep up with stunning progress in obesity science. Scientists and obesity medicine experts are promising us a tantalizing future for obesity care while the present circumstances facing real people living with […]
August 11, 2023 — Calm in the midst of a storm is always odd. Has it passed? Or is there more to come? Bedlam pretty much defines the market for obesity care right now. Both Novo Nordisk and Lilly announced robust business results on the strength of impressive new options for treating obesity. Novo released stunning topline results for […]
July 28, 2023 — Obesity care is in an awkward phase. Science has advanced to provide a better understanding of this complex disease and better tools to treat it. But health systems and public understanding can’t keep up. As a result, very effective new obesity medicines exist behind walls that keep most people from receiving their benefits. For now, […]
